1254367-74-2

Upstream product

• 100-51-6 benzyl alcohol 
• 53369-71-4 N,N,2,2-tetramethyl-1,3-propanediamine 
• 1254367-43-5 C₂₀H₁₇NO₄ 
• 1254367-38-8 phenyl 5-(benzyloxy)-2-bromo-3-methylisonicotinate 
• 1253799-65-3 phenyl 3-(benzyloxy)-5-methylisonicotinate 
• 1253799-63-1 phenyl 3-(benzyloxy)-5-chloroisonicotinate 
• 1253799-61-9 3-(benzyloxy)-5-chloroisonicotinic acid 
• 1254367-72-0 C₂₇H₃₂FN₃O₃ 
• 1254367-70-8 phenyl 3-(benzyloxy)-2-bromo-6-fluoro-5-methylisonicotinate 
• 1254367-68-4 phenyl 2-amino-5-(benzyloxy)-6-bromo-3-methylisonicotinate 
• 1254367-40-2 phenyl 3-(benzyloxy)-2,6-dibromo-5-methylisonicotinate 
• 1254367-44-6 C₂₀H₁₆BrNO₄ 
• 852821-06-8 (4aS,8aS,9S)-3-(benzyloxy)-4a-(tert-butyldimethylsilyloxy)-9-(dimethylamino)-8a,9-dihydronaphtho[2,3-d]isoxazole-4,5(4aH,8H)-dione 
• 1254367-73-1 phenyl 3-(benzyloxy)-2-[[(benzyloxy)carbonyl][3-(dimethylamino)-2,2-dimethylpropyl]amino]-6-fluoro-5-methylpyridine-4-carboxylate 

Relevant academic research and scientific papers

8-azatetracyclines: Synthesis and evaluation of a novel class of tetracycline antibacterial agents

A novel series of fully synthetic 8-azatetracyclines was prepared and evaluated for antibacterial activity. Compounds were identified that overcome both efflux (tet(K)) and ribosomal protection (tet(M)) tetracycline resistance mechanisms and are active against Gram-positive and Gram-negative organisms. Two compounds were identified that exhibit comparable efficacy to marketed tetracyclines in in vivo models of bacterial infection.

8-AZA TETRACYCLINE COMPOUNDS

The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.